Shareholder information
Shareholder information
Find details below about Haleon plc's share buybacks.
On 27 February 2025, Haleon plc announced a capital allocation of £500 million for share buybacks during 2025.
On 21 March 2025, Haleon completed an off-market buyback of c. 44m shares from Pfizer Inc for approximately £170m.
On 28 March 2025 we announced the commencement of a share buyback programme for up to £330m. This represents the remainder of the £500m allocated to share buybacks in 2025. The first tranche of the buyback programme is for an aggregate consideration of up to £200m and commenced immediately on 28 March 2025. Further details can be read here.
A breakdown of the daily transaction details can be found here and is updated weekly during the buyback programme if shares have been repurchased within the prior week.
On 29 February 2024, Haleon plc announced a capital allocation of £500 million for share buybacks during 2024.
We returned £500m to shareholders through off-market buybacks of shares from Pfizer Inc. of £315m and £115m in March and October 2024, respectively, with the remaining £70m completed through an on-market buyback programme which commenced on 1 August 2024 and ceased on 1 October 2024.
A breakdown of the daily transaction details of the on-market buyback programme is available here.
Related
